Clinical Trial Update: Open-Label Extension of the Phase III Study With Tramiprosate (3APS) in Patients With Mild to Moderate Alzheimer's Disease [Phase 3]

View source ↗

Summary

Open-label extension update of a Phase III study evaluating tramiprosate (3APS) in patients with mild to moderate Alzheimer's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Tramiprosate (tramiprosate)

Snippet

Sponsor: Bellus Health Inc. - a GSK company | Conditions: Alzheimer's Disease | Phase 3 | Status: UNKNOWN